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Abstract
The identification of novel T cell antigens is central to basic and translational research in autoimmunity, tumor immunology,
transplant immunology, and vaccine design for infectious disease. However, current methods for T cell antigen discovery
are low throughput, and fail to explore a wide range of potential antigen-receptor interactions. To overcome these
limitations, we developed a method in which programmable microarrays are used to cost-effectively synthesize complex
libraries of thousands of minigenes that collectively encode the content of hundreds of candidate protein targets. Minigene-
derived mRNA are transfected into autologous antigen presenting cells and used to challenge complex populations of
purified peripheral blood CD8+ T cells in multiplex, parallel ELISPOT assays. In this proof-of-concept study, we apply
synthetic minigene screening to identify two novel pancreatic islet autoantigens targeted in a patient with Type I Diabetes.
To our knowledge, this is the first successful screen of a highly complex, synthetic minigene library for identification of a T
cell antigen. In principle, responses against the full protein complement of any tissue or pathogen can be assayed by this
approach, suggesting that further optimization of synthetic libraries holds promise for high throughput antigen discovery.
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Introduction
The efficient and comprehensive discovery of novel, relevant T
cell antigens in human subjects and animal model systems is
complicated by two factors. The first challenge is that peripheral
blood contains an extremely diverse T cell repertoire, with T cells
specific for a single antigen present at frequencies ranging from
one in 10
5 to one in 10
2 peripheral blood mononuclear cells
(PBMC). The potentially large ratio of irrelevant-to-relevant cells
means that a modest background response derived from the
irrelevant cell population can obscure responses from genuine, but
rare antigen specific T cells. The second challenge is that most
tissues or pathogens express hundreds or thousands of proteins,
each representing a potential T cell target antigen. Such large
numbers of potential targets are difficult to express in autologous
antigen presenting cells (APC) required for typical screening
assays.
The historical approach to these practical difficulties has been to
either reduce the complexity of the T cell population being
screened, or to reduce the number of candidate antigens being
tested. For example, reducing the complexity of the T cell
population being screened can be accomplished by arbitrarily
cloning individual T cells or creating T cell hybridomas from an
antigen responsive population [1–3]. Clones are expanded and
used as sensitive, homogenous reporters for screening large,
complex peptide or cDNA libraries. Large numbers of T cells with
a single specificity enables the discovery of rare target antigens
within the library. An alternative approach is to select one or a
very small number of ‘‘candidate antigens’’, and test these against
complex populations of T cells obtained from peripheral blood or
splenocyte preparations. The efficient expression of a single
candidate antigen in large numbers of APC allows detection of
rare T cell specificities within a mixed population [4–6]. Both of
these approaches are limited – the former, in that only a small
number of T cell specificities are assayed, and the latter, in that
only a small number of potential target antigens are tested. Hence,
we have developed a novel, high-throughput protocol using
synthetic minigene libraries capable of screening mixed popula-
tions of CD8+ T cells for responses against hundreds of proteins.
As a first test of this technology, we synthesized and screened a
library encoding all peptides from 186 genes expressed preferen-
tially in human islets using CD8+ T cells from two subjects newly
diagnosed with type I diabetes. These screens have identified two
novel T cell epitopes targeted by subjects newly diagnosed with or
at risk for type I diabetes.
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2.1. Ethics statement
This project was reviewed and approved by the Virginia Mason
Institutional Review Board, which provides IRB oversight for the
Benaroya Research Institute at Virginia Mason and Virginia
Mason Hospital. Following IRB approval, specimens were
provided to the researchers in a de-identified manner by the
Benaroya Research Institute Clinical Core Repository. Virginia
Mason Institutional Review Board (IRB) is organized and operates
in compliance with the U.S. Department of Health and Human
Services and U.S. Food and Drug Administration regulations for
the protection of human subjects as described in 45 CFR Parts 46,
160, 164 and 21 CFR Parts 50, 56, 312 and 812 and adheres to
the International Conference on Harmonisation (ICH) Good
Clinical Practice (GCP) guidelines, as applicable.
2.2. Gene selection
Selection of genes exhibiting preferential expression in human
islets was performed using custom scripts to evaluate the Novartis
GeneAtlas V2 microarray dataset (http://www.ncbi.nlm.nih.gov/
geo/) [7]. Several criteria were used to select genes for inclusion in
our library. First, all genes previously considered as potential
autoantibody targets by Wenzlau and Hutton et al. were included
[8]. The 68 genes considered by these researchers include the
known T1D T-cell and autoantibody target antigens. An
additional 111 genes were selected based upon combinations of
the percentile score (P), the entropy score (Q) and the number of
tissues expressing the gene (N). Specifically, from among the genes
not evaluated by Hutton et al., we included: a) all genes with a P-
rank in the top 100, b) all genes with the Q-rank in the top 100, c)
all genes with N,4 for which the Q-rank is in the top 400, and d)
all genes with N,10 and either the P-rank or Q-rank is in the top
200. An additional 7 genes with overlapping expression in islets
and glomeruli were added to test for autoimmune responses
against both tissues. This approach resulted in a list of 186
candidate autoantigenic gene products. Genes, with associated N-
score, P-score and Q-scores are presented in Table S1.
2.3. Library design
A minigene library was designed by extracting overlapping 33
codon open reading frames (ORFs) covering the entire coding
domain of the 186 candidate target genes. Overlaps of 10 codons
were included between adjacent minigenes, resulting in a library of
3,670 minigenes (minigene sequences are listed in Table S2).
Minigenes representing all ns SNPs with a frequency of .20% in
common populations were included. Each minigene includes in
order, a pool specific primer, a T7 promoter, Kozak start, 33
codon open reading frame (ORF), and a common primer. Unique
sense, pool-specific primers were included for groups of 10
minigenes (Table S2). Minigenes encoding overlapping coding
domains were distributed into separate pools. Antisense templates
of all minigenes were synthesized in parallel using programmable
microarrays, cleaved from the array and supplied as a single
oligonucleotide mixture [9].
2.4. Minigene library amplification and in vitro
transcription
Libraries (10 pmol) were suspended in 100 ul water with 0.1%
Tween-20. Initial amplifications of each minigene pool were
carried out in 96-well plates with each well containing a 50 ul
reaction volume. Each reaction included 200 nM pool specific
primer, 200 nM common-3 primer, 16 HerculaseH Hotstart
buffer, 200 nM each dNTP, 2 U HerculaseH hotstart polymerase
and 0.5 fmol library (1 ul/well of a 1:200 library dilution).
Minigene pools were amplified using cycling profiles of 1 cycle
of 96uC for 1 minute, 30 cycles of 96uC for 30 seconds, 53uC for
30 seconds and 72uC for 1 minute, followed by a single 72uC step
for 5 minutes. Eight randomly selected PCR products/plate were
evaluated on a 2% agarose gel. In this manner, initial PCR
reactions with 370 unique, pool-specific sense primers, each
combined individually with the common antisense primer,
subdivided the library into ordered, nonredundant arrays of 370
pools with ,10 minigenes/pool (all primers listed in Table S2).
The use of antisense templates provides complementary sequences
for the pool-specific primers, but not the common primer, thereby
limiting amplification to only the subset of minigenes selected by
an individual pool-specific primer within a single well.
A second sewing PCR reaction was performed to add a human
b-globin 39UTR and polyA sequence to each minigene using the
common primer sequence as the overlap (Fig. 1). Inclusion of 130
bases of polyT sequence on the 59 end of the antisense sewing
primer (UltramerH, Integrated DNA Technologies) eliminates the
need to polyadenylate the RNA following in vitro transcription.
Sewing PCR reactions were also performed in a 96-well format
with 50 ul reaction volumes using a cycling profile identical to the
initial PCR. Each well contained 4 ul of the initial amplification
products, a beta-globin UTR amplification product (,20 ng/
well), 200 nM of the appropriate pool specific primer and 200 nM
of the antisense UTR/polyT ultramer. Eight randomly selected
PCR products from each plate were evaluated on a 2% agarose
gel. PCR products were purified using a Qiagen Minelute
H 96-UF
PCR purification kit according to the manufacturer’s instructions.
Ambion T7 mMessage mMachine
H kits were used to produce
capped, polyadenylated transcripts from each minigene pool.
Reactions were assembled in 96 well plates with a final volume of
20 ul/well using 3 ul of purified minigene pool/reaction as a
template. IVT (in vitro transcription) plates were incubated for
3 hours at 37uC. Randomly selected IVT products were briefly
heated at 65uC and evaluated on a 2% agarose gel. IVT reactions
were immediately frozen pending transfections. IVT reactions do
not require purification prior to transfection.
2.5. T cell and B cell purification
Two newly diagnosed subjects (ND2, ND3, both within 12
months of T1D diagnosis) were provided for screening by the
Diabetes Clinical Research Consortium Repository at the
Benaroya Research Institute. PBMC from fresh 200 ml blood
draws were purified using ficoll density centrifugation and CD8+
T cells were purified using a human CD8+ positive selection kit
from Dynal. T cells were immediately frozen in aliquots of 10 and
20610
6/cryovial (.97% purity).
Cultures of B cells from each subject were expanded for use as
antigen presenting cells (APC) by co-culture of CD8-depleted
PBMC on irradiated CD40L expressing L cells [10] in the
presence of 10 ng/ml of human IL-21 (Preprotech) and 1.25 mg/
ml of Cyclosporin A (Sigma). Expansion cultures were incubated
for 2 weeks and non-adherent cells were evaluated by flow
cytometric analysis. CD40L and IL-21 stiumulation promoted B
cell expansion and the Cyclosporin A prevented T cell
proliferation leading to cultures that were .90% CD19+ and
DR+.
2.6. Transfection (Nucleoporation) of minigene pool IVT
products
Nucleoporations were carried out using an AMAXA 96-well
shuttle and an AMAXA B cell kit. Each nucleoporation included
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29949Figure 1. Overview of synthetic minigene screening. a) Libraries are synthesized on programmable microarrays, cleaved from the chip surface
and provided as a single mixture of antisense oligonucleotide templates. b) Initial 96 well PCR reactions utilize individual sense, pool specific primers
(green, purple, orange arrows) in combination with a common primer (red arrows) to amplify specific pools of antisense templates (multicolor
regions) from the mixed oligo library. Synthesis of a complement for the common primer is dependent upon synthesis of the sense strand primed by
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5 autologous CD40L-expanded B cells resuspended in freshly
mixed nucleoporation solution and 3 ul IVT reaction. Nucleo-
porations were performed using an AMAXA-96 well shuttle and
program E101. After nucleoporation the cells were rested for
10 minutes before being placed into pre-warmed tissue culture
media. Wells nucleoporated with a GFP encoding plasmid were
evaluated by flow cytometric analysis the following day. Trans-
fection efficiencies of .70% GFP expressing, viable cells are
commonly achieved.
2.7. Minigene-based cultured IFNc ELISPOT assay
2610
5 irradiated (3000 rads), transfected B cells were placed
into 96-well round bottom plates with 2610
4 autologous CD8
+ T
cells and 10 ng/mL of rhIL-15 for 7–14 days. Typical survival of B
cells following nucleoporation was ,20% yielding 2–4610
4 viable
APC/well. After 7–14 days, additional non-irradiated B cells were
nucleoporated with the same IVT pools used for in vitro
stimulations. Each well of stimulated T cells was re-challenged
in an IFNc ELISPOT with 2610
5 transfected B cells expressing
the same minigene pool used for stimulation. ELISPOT plates are
incubated for 16–18 hours and developed according to manufac-
turer’s instructions (BD Biosciences).
2.8. Peptide-based ‘‘direct’’ IFNc ELISPOT assay
Direct IFNc ELISPOT assays do not include an in vitro
stimulation prior to ELISPOT. The direct IFNc ELISPOT assay
used 1610
6 total PBMC+peptide (purchased from Sigma) as both
responder and APC populations. ELISPOTs were incubated
overnight with 10 mg/ml of the indicated peptides and developed.
For assays testing T cell recognition of GLIPR1 (4–12), 1610
6 T2
cells were loaded with peptide at room temperature for 2 hours,
washed to remove free peptide and mixed with 1610
5 CD8+ T
cells overnight. Direct ELISPOTs were developed with a slight
modification of the protocol used to develop cultured ELISPOT
plates. Briefly, following addition of the biotinylated detection
antibody and SA-HRP, plates were washed and exposed to a
biotinylated anti-avidin D antibody (5 mg/ml) for 1 hour. After
washing, plates were exposed to SA-HRP a second time, washed
and developed with AEC reagent in the same manner as all
previous ELISPOTs.
2.9. T2 Binding assay
To determine binding specificity of peptides for HLA-A*0201,
1610
6 T2 cells were incubated with 20 mg/ml of the indicated
peptide in media for 4 hours at 37uC. Influenza matrix peptide
(58–66) was used as a positive control for binding [11] and no
peptide was used as the negative control. Cells were washed with
PBS and then stained with FITC-anti-HLA-A2 (BB7.2; BDBios-
ciences) for 20 minutes at 4uC. Surface HLA levels were then
assessed on a FACSCalibur and analyzed using Flowjo software.
2.10. Statistics
A positive response to an experimental compared to control
peptide was determined by ranking log transformed assay results
by p-values calculated from moderated t-statistics comparing
triplicates of each experimental peptide to triplicates of its matched
control peptide using the approach implemented in the R package
Limma [12]. P-values were then adjusted for multiple comparisons
using the algorithm of Benjamini and Hochberg [13] to calculate
false discovery rates (FDR). This approach for ranking and
calculating FDR’s have been shown to be more conservative than
standard permuted t-tests for experiments with small samples [14].
Diagnostic plots (qqnorm; R package) were used to assure that in
the average of all control triplicates approximated a normal
distribution. Samples with a false discovery rate under 0.05 were
considered positive responses.
Results
3.1. Outline of protocol
To increase the efficiency by which the full matrix of potential T
cell-antigen interactions can be explored, we developed the novel
approach diagrammed in Figure 1. Briefly, overlapping mini-
genes are designed to encode all potential peptide epitopes derived
from hundreds of selected proteins expressed in the tissue or
pathogen of interest. Long oligonucleotides encoding these
minigenes are synthesized in parallel on a programmable
microarray, and then released from the array as a single mixture
[15] (Fig. 1a). Subsets of minigenes are amplified from this mixture
to generate ordered 96-well arrays of minigene pools, with 10
defined minigenes per pool, i.e. ,960 minigenes per plate (Fig. 1b,
c). Each pool is transcribed in vitro (IVT) with a cap analogue,
thereby synthesizing defined pools of fully translatable mRNAs
(Fig. 1d). IVT products from each pool are transfected into
irradiated autologous B cells in a 96-well format for use as antigen
presenting cells (APC) (Fig. 1e). Transfected minigene-derived
mRNAs direct cytoplasmic expression of 33 residue peptides,
which are processed and presented by the endogenous MHC class
I pathway. Minigene-expressing B cells are utilized to challenge
purified CD8+ T cells in a cultured, IFNc ELISPOT (Fig. 1e).
Minigene pools stimulating IFNc release significantly above
controls are scored as positive and subjected to deconvolution
assays designed to identify the targeted peptide antigen within a
given pool. This approach is effectively a highly multiplexed
candidate antigen screen, and allows a large number of potential
antigens to be tested against complex mixtures of T cells in a high-
throughput fashion.
3.2. Screening a minigene library with CD8+ T cells from
T1D patients
As a proof-of-concept, we constructed a minigene library
encoding 186 human pancreatic islet genes. The library was
screened with CD8+ T cells from two subjects newly diagnosed
with type I diabetes (T1D). Candidate antigens were selected using
tissue expression microarrays to identify candidates exhibiting
preferential expression in human islets (Materials and Meth-
ods 2.2.) [8,16]. The minigene library was designed to encode
overlapping 33 residue peptides representing the entire peptide
a single, unique pool-specific primer in each well. This subdivides the library into ordered arrays of minigene pools, with 10 defined minigenes/well. c)
A second PCR reaction sews a stop codon and a human beta-globin 39 UTR (purple+gold boxes) onto each minigene using the common primer
domain as an overlap. PCR is driven by the sense pool specific primer, and an antisense primer extending from a 130 base oligo dT tail through the 39
end of the UTR. Inclusion of an oligo dT tail on the antisense strand encodes a polyA template on the end of each mature minigene. This template
allows synthesis of poly-adenylated mRNA during in vitro transcription. d) Arrays of minigene pools are purified and subject to in vitro transcription in
the presence of a cap analogue, producing an array of defined, fully translatable mRNA pools. e) IVT products are transfected into autologous CD40L
expanded B cells for use as antigen presenting cells. Transfected APCs are used as stimulators and targets for in vitro stimulations and IFNc ELISPOT
assays.
doi:10.1371/journal.pone.0029949.g001
T Cell Screening Using Minigene Libraries
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e29949complement of the 186 selected genes and all variations with
frequencies of .20% (Tables S1 & S2). Amplification and in vitro
transcription resulted in 370 minigene-derived mRNA pools.
Primary screening of the entire library was performed using a
cultured IFNc ELISPOT in which T cells were first stimulated
with irradiated APC expressing minigenes from a single pool,
cultured for one week to expand T cells responsive to minigene-
encoded antigens, and then rechallenged with the same APC/
minigene pool in an IFNc ELISPOT assay (Fig. 2, panels a and
b). These experiments identified 19 and 12 pools stimulating IFNc
release 5 standard deviations above wells stimulated with mock
transfected APCs (Table 1). Three targeted pools common to
both subjects included peptides derived from 4 genes not known to
be T1D autoantigens - SCG3, ELL2, PPP1R1A and SERPIN3A.
Pools containing minigenes derived from two known T1D
autoantigens, CPE and PTPRN/IA2, also scored positive.
3.3. Deconvolution of positive wells from the primary
screen
Individual minigenes within the pools scoring positive in the
primary screen were amplified using minigene-specific primers,
then rebuilt into full minigenes using stepout primers. Each
individual minigene was then retested in triplicate to identify those
stimulating a reproducible response. Cultured ELISPOT assays
clearly confirmed responses against individual minigenes from two
pools targeted by T cells from subject ND2, one derived from
epithelial adhesion molecule, EpCAM in pool #308, and another
encoding a portion of glioma pathogenesis associated protein,
GLIPR1 in pool #85 (Fig. 2, panels c and d). It is interesting to
note that the majority of putatively positive pools from the primary
screen did not clearly yield a unique targeted minigene during
deconvolution. The reason for this variability remains unknown,
but may include low precursor frequencies of T cells specific for
individual target epitopes, variable transfection efficiency and/or
death rates of transfected APCs, errors within the library, or
detection of rare responses against components of the IVT
reactions or transfection solution. Nevertheless, even with the
apparent high false positive rate we were able to detect two novel
epitopes using this technology.
3.4. Identifying GLIPR1 and EpCAM epitopes and
determining HLA-A2 binding
The two confirmed minigene targets each encoded unique, 33
residue peptides, VRTYWIIIELKHKAREKPYDSKSLRTALQ-
KEIT from EpCAM (139–171, blue residues in Fig. 2 c) and
MRVTLATIAWMVSFVSNYSHTANILPDIENEDF from GLI
PR1 (1–33, red residues in Fig. 2 c). To further define the domain
containing the minimal peptide epitope, we tested sequential 15
residue peptides with 11 residue overlaps in a direct IFNc
ELISPOT assay. This assay evaluates responses in unselected
PBMC from the responding subject without an in vitro stimulation
prior to the ELISPOT assay, and is therefore thought to be a more
accurate assessment of ongoing immune reactivity in vivo. Two 15
residue GLIPR1 peptides overlapping by 11 residues, and a single
15 residue peptide derived from EpCAM, elicited significant
responses (Fig. 2, panels e and f).
Because additional blood draws were unavailable from the
subject used for discovery, we next tested overlapping 9 and 10
residue peptides from each reactive 15 residue peptide in multiple
cases and controls. These studies identified a single epitope from
each gene, TLATIAWMV for GLIPR1 (4–12), and RTYWIIIEL
for EpCAM (140–148), as stimulating significant responses in
newly diagnosed or at-risk subjects (an at-risk individual was
defined as a person with a first degree relative with T1D having
one autoantibody specific for a known T1D autoantigen) but
rarely in controls (Fig. 3, panels a and b). Responses against
GLIPR1 (4–12) were found to be significant in 2 of the 9 T1D
cases; p-values 0.001 and 0.005 corresponding to FDR’s of 0.011
(T1D#2) and 0.030 (T1D#8), respectively. One control individ-
ual (Control #12) out of 26 patients was also significant by p-value
but it was not significant by FDR while no at-risk individuals were
significantly different compared to the control peptide (Fig. 3a).
There was no statistically significant response against EpCAM
(140–148) in the T1D or control groups (Fig. 3b). Although, one
at-risk subject had a significantly higher response against the
indicated EpCAM peptide compared to a control peptide (at-risk
#2) (p,0.05), this response was not significant by FDR. However,
these data were generated without knowledge of the HLA class I
alleles presenting each peptide eptiope. Assessing multiple cases
and control subjects, all of which share the class I alleles presenting
these peptides may reveal an elevated association with disease for
GLIPR1 (4–12) and possibly EpCAM (140–148). Importantly, the
consistent responses observed against minigene pools, individual
minigenes and overlapping peptides in both cultured and direct
ELIPOT assays for both GLIPR1 and EpCAM epitopes
demonstrates that synthetic minigene screening identifies genuine,
novel CD8+ T cell target epitopes.
Epitope prediction using BIMAS and SYFPEITHI suggested
that the GLIPR1 epitope may be presented by HLA-A2 [17,18].
We tested bothGLIPR1 and EpCAM epitopes for binding to and
presentation by HLA-A*0201 using T2 cells [19,20]. T2 cells are
TAP deficient cells that solely express HLA-A*0201 and therefore
have low levels of empty HLA-A*0201 on their surface. Loading
T2 cells with exogenous peptide capable of binding HLA-A*0201
stabilizes the MHC class I molecule on the surface, leading to a
detectable increase in HLA-class I surface staining. GLIPR1 (4–
12), but not EpCAM (140–148) increased HLA-A*0201 surface
staining, suggesting that GLIPR1 (4–12), but not EpCAM (140–
148) can be presented by HLA-A*0201 (Fig. 3c, and data not
shown). Furthermore, T2 cells loaded with GLIPR1 (4–12) were
capable of stimulating IFNc release by CD8+ T cells derived from
responders identified in Figure 3A (Fig. 3d). Presentation of
GLIPR1(4–12) by HLA-A*0201 is therefore sufficient for T cell
recognition.
The subject used for discovery of EpCAM and the single at-risk
subject with low but detectable responses to EpCAM 140–148
shared a single HLA class I allele, HLA-B*1501. Studies testing
HLA-B*1501 for presentation of EpCAM 140–148 are ongoing.
Interestingly, EpCAM is known to be upregulated during islet
development and in many tumor types including insulinomas,
suggesting that T cell responses against autoantigens induced
during islet regeneration may be significant markers for disease
progression [21,22]. While both T cell and autoantibody responses
against EpCAM have been reported in cancer patients, there have
been no previous reports of immune responses against either
EpCAM or GLIPR1 in subjects with type I diabetes [23–25],
highlighting the ability of synthetic minigene screening to identify
truly novel antigens.
Discussion
Synthetic minigene screening can be immediately applied for
CD8+ T cell antigen discovery in any system in which a rational
selection of hundreds of candidate proteins, or tens of thousands of
potential epitopes, can be made. In the example presented here,
candidate antigens were chosen using expression array profiles to
select genes exhibiting preferential expression in the target tissue,
T Cell Screening Using Minigene Libraries
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29949T Cell Screening Using Minigene Libraries
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29949human islets [8]. However, a variety of other approachesto candidate
antigen selection can be envisioned, including libraries selecting
epitopes predicted to bind particular MHC alleles, peptides stripped
from MHC and identified using mass spectrometry, or candidate
minor antigenic peptides derived through genotyping of matched
transplant donor and recipient pairs, i.e. candidate minor histocom-
patibility antigens. Indeed, libraries encoding the entire protein
complement of pathogens with smallgenomes can be assembled with
reagents and methodologies currently available.
Although programmable microarrays have previously been used
to cost-effectively synthesize complex libraries of DNA and RNA
species [15], to our knowledge this is the first study to use
programmable microarrays to generate complex populations of
polypeptides for discovery of T cell antigens. Although synthesis
lengths remain limited, i.e. up to 200 bp, this length is sufficient to
encode both polypeptides and supporting sequences for T cell
antigen screening as described here (Fig. 1). The upper limit to
the number of different proteins that can be screened is unknown
but is not limited by the number of custom oligos that can be
synthesized. Indeed, highly accurate libraries of as many as
55,0006150 bp oligonucleotides have been synthesized [9].
Experiments exploring larger minigene pool sizes are ongoing,
and it is also possible that multiplex gene assembly [26],
combinatorial pooling strategies [27], and optimized APC
populations will increase the number of candidates that can be
efficiently screened in the near future. In addition, minigene
libraries directing synthesis of candidate peptides fused to
autophagosomal targeting signals or secretory signals may allow
discovery of CD4+ T cell epitopes [26,28,29].
One drawback to minigene screening is the current high cost
and limited availability of long, accurate oligonucleotide libraries.
However several vendors offer custom, complex oligonucleotide
libraries for targeted sequence capture which may be suitable for
minigene library construction. One critical parameter affecting the
performance of minigene libraries is the error rate within the
mixed oligonucleotide library template. While error rates in
oligonucleotide mixtures synthesized on microarrays as low as 1 in
300 have been achieved, error rates of between 1 and 2% are
Table 1. Responses to GLIPR1 4–12 and EpCAM 140–148 incases and controls, and HLA restriction studies.
ND2.5 STD over mock ND3.5 STD over mock ND3
spot # gene Pool #l spot # gene Pool #l
131 SORL1 137 145 HPN/TTFG3 35
35 OLFM4/ENO2 249 51 TOB1/PTPRN 289
32 CPE/CUZD1/NPY 330 50 ns SNP pool #361 361
29 WNT4/RAMP2/APOH 349 38 SERPINA3/PPPIR1A 103
27 ACPP/GLIPR1 85 38 PNLIPRP2/PRPH 337
26 SCG2 263 28 PTPRN 290
22 APLP1/EPCAM 308 25 GLIPR1/DNAJC12/STC1 87
21 PRPH/VGF 340 22 SCG3/ELL2 9
19 SYT13/FOXA1 2 22 CLDN7/KCNMB2/ATP2A3 297
18 SCG3/ELL2 9 21 C6 301
16 SERPINA3/PPPIR1A 104 19 PPPIR1A 106
13 PPPIR1A 106 19 INPP5E 27
13 PAPSS2/ELA2A 194
12 MNX1/CXCL2/CTRB2 296
12 ns SNP pool # 369 369
11 SERPINA3/PPPIR1A 103
11 PROM1 253
11 CLDN7/KCNMB2/ATP2A3 298
10 OLFM4/ENO2 250
Spot number and minigene source for provisionally positive minigene pools. Each score represents a single cultured ELISPOT well stimulated with minigenes derived
from the indicated genes. Minigenes in each pool are listed in Table S2. Positive scores exceeded 5 standard deviations of mean scores of wells stimulated with mock
transfected autologous B cells. Pool number 9, 103 and 106 scored positive in both subjects.
doi:10.1371/journal.pone.0029949.t001
Figure 2. Screening and pool deconvolution ELISPOTs. Screening: a) and b) are bar graphs of primary screening results from two newly
diagnosed T1D subjects. Panel a) is subject ND2, panel b) is subject ND3. Each bar represents the IFNc spot number for an individual cultured ELISPOT
well stimulated with a single minigene pool. Red line indicates 56standard deviations of wells stimulated with mock transfected autologous B cells.
Red circles indicate three wells that scored positive in both screens. Deconvolution c) and d): cultured IFNc ELISPOT assays testing ND2-derived
CD8+ T cell responses against individual minigenes from c) pool 85 and d) pool 308. Individual minigenes were amplified using minigene specific
primers. Subsequent PCR reactions added T7 and common sequences, and full length individual minigenes were rebuilt and tested as described in
Fig. 1. Targeted minigenes encode 33 residue peptides displayed in red. Peptide epitope mapping e) and f): Direct IFNc ELISPOT assays testing
overlapping 15 residue peptides from GLIPR1 and EpCAM minigenes targeted in b) and c). Peptides were tested in triplicate using a direct 24 hour
IFNc ELISPOT assay with 1610
5 CD8+ T cells/well. Purple residues indicate non-antigen derived sequences encoded by minigene flanking sequences.
Red residues indicate 9 residue peptide epitope identified in subsequent epitope mapping experiments.
doi:10.1371/journal.pone.0029949.g002
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deletions and single nucleotide substitutions. In some cases, non-
uniform error rates have been observed, with a higher rate of
errors near the 39 end of sequences within a library versus the 59
end. This may be due to the increased number of deblocking
cycles experienced by the 39 end of each oligonucleotide, resulting
in a higher cumulative substitution rate near the solid support.
Sequencing the amplified library with next generation sequencing
Figure 3. Responses to GLIPR1 4–12 and EpCAM 140–148 in cases and controls, and HLA restriction studies. Responses to a) GLIPR1
(4–12) b) and EpCAM (140–148) in T1D, at risk and control subjects. In both panels, PBMCs from the indicated patient groups were stimulated with
GLIPR1 or EpCAM peptides (filled bars) vs. control peptide (open bars) overnight. Anti-CD3/CD28 stimulation was used as a positive control and all
responses to antibody stimulation were too numerous to count (data not shown). The graphs display the average raw number of spots from triplicate
wells +/2 the standard error. The (*) indicates for a given patient that the experimental peptide responses were significantly higher (FDR ,0.05) than
the response to the control peptide. The number of patients who significantly responded to the each experimental peptide is indicated by the
fraction in the graph. PBMC from subject ND2 used for discovery of each epitope were not available and are not included in these graphs. c) HLA-
A*0201 binding assay for GLIPR1 epitope TLATIAWMV on T2 cells. 1610
6 T2 cells were incubated with 20 mg/ml of the indicated peptide in media for
4 hours at 37uC, stained for HLA-A*0201 and evaluated by flow cytomety. d). Presentation of GLIPR1 eptiope by HLA A*0201. T2 cells were loaded
with 10 mg/ml GLIPR1 epitope TLATIAWMV or control epitope from pyruvate dehydrogenase for two hours at room temperature, washed and mixed
with purified CD8+ T cells from one responding subject (T1D #2) in a direct IFNc assay and was found to be statistically significant compared to the
control peptide (FDR,0.05).
doi:10.1371/journal.pone.0029949.g003
T Cell Screening Using Minigene Libraries
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29949technologies will be required to reveal the overall error rate and
error distribution within this library. Application of enzymatic or
MutS-based error correction strategies are expected to dramati-
cally improve the accuracy of future libraries [30,31]. Other than
the libraries, the most costly reagents for synthetic minigene
screening are the capped IVT kits, and the kits used for
transfection of IVT products into APC. We estimate that a
minigene screen of this scale costs approximately $10,000.
However, a conservative estimate for synthesis of an equivalent
overlapping peptide library would be in excess of $36,0000
(assuming $10/33 residue peptide63669 peptides). Furthermore,
the peptide library represents a finite resource, while a minigene
library can be screened indefinitely for the additional cost of
reagents for PCR, in vitro transcription and transfection.
A major outstanding question is the issue of false positive signals
in the primary screen. It is interesting to note that each subject had
multiple pools that scored positive in primary screens that were not
clearly confirmed in initial deconvolution experiments, including
two pools generating .100 spots in the primary screen. While
experimental variation/error may have obscured deconvolution of
pools with moderate spot numbers in cultured IFNc ELISPOT
screens (,30 spots), it might be expected that if genuine, the
largest two responses would remain detectable in secondary assays.
These results strongly suggest that false positive responses are
occurring in the cultured ELISPOT screen albeit at an unknown
frequency. This is not necessarily surprising, as ELISPOT assays
are highly sensitive to a wide variety of factors [32–34]. In
addition, the large number of individual tests performed in the
primary screen may lead to detection of rare responses against
materials/proteins derived from components of either the IVT
reaction or the transfection solution itself. We are now performing
experiments with purified IVT products, as well as with libraries in
which each minigene is duplicated such that all possible pairs of
pools have either one or zero minigenes in common. Duplications
in this manner may reduce the number of false positive responses
detected, while streamlining the deconvolution steps as well. Other
possible variations in the protocol include using cell lines as APCs
(such as K56A2 cells stably expressing HLA-A*0201 [35]) and
eliminating the in vitro stimulation prior to the ELISPOT. This
change may require use of greater numbers of CD8+ T cells/well
(approx. 1–2610
5/well versus the 2610
4/well used here) for
detection of low frequency CD8+ T cells. These modifications may
ultimately reduce the number of false positives detected in the
primary screen, thereby reducing the effort and costs associated
with confirmation, deconvolution and validation.
High throughput-screening for novel T cell target antigens has
been a major bottleneck for multiple subfields of immunological
research, including cancer immunology, infectious disease,
autoimmunity and transplantation. Initial studies presented here
suggest that synthetic minigene library technology promises to
overcome many of the difficulties associated with traditional
screening techniques, immediately increasing the number of
candidate T cell antigens amenable for screening from a handful
of candidates to several hundred proteins or several thousand
epitopes. We envision that extensions and improvements of this
approach will enable comprehensive screens, i.e. all possible
peptide epitopes represented in the full protein complement
encoded by a pathogen or by a human genome.
Supporting Information
Table S1 The Gene name, Affymetrix probeset number,
percentile score (P), the entropy score (Q), P and Q ranking,
and the number of tissues expressing the gene (N) are presented for
each of 186 genes evaluated. The source column indicates whether
the gene was evaluated by Wenzlau and Hutton (listed as H,
reference 8), or was identified using a combination of P, N and Q
scores (listed as P) as described in materials and methods, or was
chosen as being co-expressed in islets and glomeruli (listed as G).
(XLS)
Table S2 Table S2 lists the nucleotide sequences of pool specific
primers, common primer, minigene templates and primers used
for assembly of the library.
(XLS)
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